Sildenafil citrate, which is also known by the brand names Revatio and Viagra, is a treatment for pulmonary arterial hypertension (PAH). PAH sometimes occurs as part of systemic scleroderma, which is a connective tissue disease.(Also see: What is PAH?, What is Scleroderma? and PAH Treatments)
Revatio (sildenafil) is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH). When taken as directed, Revatio may improve your ability to exercise and may slow down worsening changes in your physical condition. Pfizer.
Adding Bosentan to Sildenafil for PAH: What's the Verdict? Despite the failure of the present trial with respect to the primary endpoint, the improvement on the 6-minute walk suggests to the practicing physician that the sildenafil/bosentan combination may be worth a trial in a patient in whom monotherapy has not provided acceptable results. Medscape, 12/16/2015. (Also see: Bosentan)
Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. Incremental shuttle walking distance was superior during treatment with Sildenafil plus Ambrisentan than during treatment with Sildenafil plus Bosentan. There were no concerns about safety with either combination therapy regime. Wiley, Clin Transl Sci, 2016 Feb;9(1):29-3.
FDA Drug Safety Communication: FDA clarifies Warning about Pediatric Use of Revatio (sildenafil) for Pulmonary Arterial Hypertension. Our 2012 warning was to raise awareness of clinical trial results showing a higher risk of mortality in pediatric patients taking a high dose of Revatio when compared to pediatric patients taking a low dose. It was not intended to suggest that Revatio should never be used in children; however, some health care professionals have interpreted this information as a contraindication, and have refused to prescribe or administer the drug. We recognize there may be situations in which the benefit-risk profile of Revatio may be acceptable in individual children. FDA.
FDA Warns About Sildenafil in Kids with pulmonary arterial hypertension (PAH). The FDA cautioned late Thursday against using sildenafil (Revatio) to treat pulmonary arterial hypertension in patients younger than 17, after an unexpectedly high rate of mortality was seen among children receiving the drug in high doses in a clinical trial. MedPageToday, 08/31/12.
Reading Voices of Scleroderma Books: Diana Kramer.
Sharing Scleroderma Awareness Bracelets: Deb Martin, Brenda Miller, Vickie Risner.
Thanks to UNITED WAY donors of Central New Mexico and Snohomish County!
Patricia Ann Black: Marilyn Currier, Shelley Ensz, Richard Howitt, Gerald and Pat Ivanejko, Juno Beach Condo Association, Keith and Rosalyn Miller, and Elaine Wible.
Gayle Hedlin: Daniel and Joann Pepper and Nancy Smithberg.
Janet Paulmenn: Anonymous, Mary Jo Austin, Shelley Blaser, Susan Book, Dennis and Pat Clayton, Grace Cunha, Cindy Dorio, Michael and Patricia Donahue, Shelley Ensz, Nancy Falkenhagen, Jo Frowde, Alice Gigl, Margaret Hollywood, Karen Khalaf and Family, Susan Kvarantan, Bradley Lawrence, Jillyan Little, Donna Madge, Michele Maxson, Barry and Judith McCabe, John Moffett, My Tribute Foundation, Joan-Marie Permison, John Roberts, Margaret Roof, Maryellen Ryan, Mayalin and Kiralee Murphy, Nancy Settle-Murphy, and Bruce and Elizabeth Winter.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content.